275 related articles for article (PubMed ID: 36785761)
1. Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy.
Phillips NA; Rocktashel M; Merjanian L
Drug Des Devel Ther; 2023; 17():363-367. PubMed ID: 36785761
[TBL] [Abstract][Full Text] [Related]
2. Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis.
Azie N; Angulo D; Dehn B; Sobel JD
Expert Opin Investig Drugs; 2020 Sep; 29(9):893-900. PubMed ID: 32746636
[TBL] [Abstract][Full Text] [Related]
3. Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis.
Barnes KN; Yancey AM; Forinash AB
Ann Pharmacother; 2023 Jan; 57(1):99-106. PubMed ID: 35502451
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis.
Nyirjesy P; Schwebke JR; Angulo DA; Harriott IA; Azie NE; Sobel JD
Clin Infect Dis; 2022 Jul; 74(12):2129-2135. PubMed ID: 34555149
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Kan S; Song N; Pang Q; Mei H; Zheng H; Li D; Cui F; Lv G; An R; Li P; Xiong Z; Fan S; Zhang M; Chen Y; Qiao Q; Liang X; Cui M; Li D; Liao Q; Li X; Liu W
Mycopathologia; 2023 Apr; 188(1-2):99-109. PubMed ID: 36378354
[TBL] [Abstract][Full Text] [Related]
6. Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).
Schwebke JR; Sobel R; Gersten JK; Sussman SA; Lederman SN; Jacobs MA; Chappell BT; Weinstein DL; Moffett AH; Azie NE; Angulo DA; Harriott IA; Borroto-Esoda K; Ghannoum MA; Nyirjesy P; Sobel JD
Clin Infect Dis; 2022 Jun; 74(11):1979-1985. PubMed ID: 34467969
[TBL] [Abstract][Full Text] [Related]
7. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates.
Waikhom SD; Afeke I; Kwawu GS; Mbroh HK; Osei GY; Louis B; Deku JG; Kasu ES; Mensah P; Agede CY; Dodoo C; Asiamah EA; Tampuori J; Korbuvi J; Opintan JA
BMC Pregnancy Childbirth; 2020 May; 20(1):266. PubMed ID: 32375724
[TBL] [Abstract][Full Text] [Related]
9. Ibrexafungerp: A new triterpenoid antifungal.
Sucher AJ; Thai A; Tran C; Mantena N; Noronha A; Chahine EB
Am J Health Syst Pharm; 2022 Dec; 79(24):2208-2221. PubMed ID: 36083109
[TBL] [Abstract][Full Text] [Related]
10. Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306.
Goje O; Sobel R; Nyirjesy P; Goldstein SR; Spitzer M; Faught B; Larson S; King T; Azie NE; Angulo D; Sobel JD
J Womens Health (Larchmt); 2023 Feb; 32(2):178-186. PubMed ID: 36255448
[No Abstract] [Full Text] [Related]
11. Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp.
Grant LM; Orenstein R
J Investig Med High Impact Case Rep; 2022; 10():23247096221123144. PubMed ID: 36059275
[TBL] [Abstract][Full Text] [Related]
12. A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana.
Adjapong G; Hale M; Garrill A
Med Mycol; 2017 Aug; 55(6):686-689. PubMed ID: 27838642
[TBL] [Abstract][Full Text] [Related]
13. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
Mendling W; Brasch J; Cornely OA; Effendy I; Friese K; Ginter-Hanselmayer G; Hof H; Mayser P; Mylonas I; Ruhnke M; Schaller M; Weissenbacher ER
Mycoses; 2015 Mar; 58 Suppl 1():1-15. PubMed ID: 25711406
[TBL] [Abstract][Full Text] [Related]
14. Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines.
Nyirjesy P; Brookhart C; Lazenby G; Schwebke J; Sobel JD
Clin Infect Dis; 2022 Apr; 74(Suppl_2):S162-S168. PubMed ID: 35416967
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).
Sobel R; Nyirjesy P; Ghannoum MA; Delchev DA; Azie NE; Angulo D; Harriott IA; Borroto-Esoda K; Sobel JD
BJOG; 2022 Feb; 129(3):412-420. PubMed ID: 34676663
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Candida albicans and non-albicans isolates from vaginal secretions: comparative evaluation of colonization, vaginal candidiasis and recurrent vaginal candidiasis in diabetic and non-diabetic women.
Gunther LS; Martins HP; Gimenes F; Abreu AL; Consolaro ME; Svidzinski TI
Sao Paulo Med J; 2014; 132(2):116-20. PubMed ID: 24714993
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of CDR1 and MDR1 efflux pump genes and fluconazole resistance are involved in recurrence in Candida albicans-induced vulvovaginal candidiasis.
Esfahani A; Omran AN; Salehi Z; Shams-Ghahfarokhi M; Ghane M; Eybpoosh S; Razzaghi-Abyaneh M
Diagn Microbiol Infect Dis; 2024 May; 109(1):116242. PubMed ID: 38452558
[TBL] [Abstract][Full Text] [Related]
18. In vivo activity of Sapindus saponaria against azole-susceptible and -resistant human vaginal Candida species.
Damke E; Tsuzuki JK; Cortez DA; Ferreira IC; Bertoni TA; Batista MR; Donati L; Svidzinski TI; Consolaro ME
BMC Complement Altern Med; 2011 May; 11():35. PubMed ID: 21542936
[TBL] [Abstract][Full Text] [Related]
19. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy.
Goswami D; Goswami R; Banerjee U; Dadhwal V; Miglani S; Lattif AA; Kochupillai N
J Infect; 2006 Feb; 52(2):111-7. PubMed ID: 15908007
[TBL] [Abstract][Full Text] [Related]
20. Ibrexafungerp: First Approval.
Lee A
Drugs; 2021 Aug; 81(12):1445-1450. PubMed ID: 34313977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
